Stephens analyst Mason Carrico has begun coverage of Procept BioRobotics (PRCT, Financial) with an "Overweight" rating and set a price target of $70. The firm anticipates significant growth and improvement in profit margins as the adoption of the company's Aquablation technology continues to increase. This technology is making notable inroads into the benign prostatic hyperplasia market by drawing patients away from traditional procedures and attracting those who have previously postponed or avoided surgery.
Furthermore, Stephens highlights the company's potential expansion into treating prostate cancer as a substantial opportunity for long-term growth. This strategic move could significantly boost Procept's market presence and financial performance in the years to come.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for PROCEPT BioRobotics Corp (PRCT, Financial) is $78.33 with a high estimate of $90.00 and a low estimate of $60.00. The average target implies an upside of 35.27% from the current price of $57.91. More detailed estimate data can be found on the PROCEPT BioRobotics Corp (PRCT) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, PROCEPT BioRobotics Corp's (PRCT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for PROCEPT BioRobotics Corp (PRCT, Financial) in one year is $137.07, suggesting a upside of 136.69% from the current price of $57.91. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the PROCEPT BioRobotics Corp (PRCT) Summary page.
